These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15377973)

  • 1. Salbutamol and the competitive athlete.
    McKenzie DC
    Clin J Sport Med; 2004 Sep; 14(5):316. PubMed ID: 15377973
    [No Abstract]   [Full Text] [Related]  

  • 2. Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete.
    Schweizer C; Saugy M; Kamber M
    Clin J Sport Med; 2004 Sep; 14(5):312-5. PubMed ID: 15377972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control.
    Ventura R; Segura J; Bergés R; Fitch KD; Morton AR; Berruezo S; Jiménez C
    Ther Drug Monit; 2000 Jun; 22(3):277-82. PubMed ID: 10850394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical methodology for enantiomers of salbutamol in human urine for application in doping control.
    Bergés R; Segura J; de la Torre X; Ventura R
    J Chromatogr B Biomed Sci Appl; 1999 Feb; 723(1-2):173-84. PubMed ID: 10080644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment.
    Bergés R; Segura J; Ventura R; Fitch KD; Morton AR; Farré M; Mas M; de La Torre X
    Clin Chem; 2000 Sep; 46(9):1365-75. PubMed ID: 10973867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The enigma of inhaled salbutamol and sport: unresolved after 45 years.
    Fitch KD
    Drug Test Anal; 2017 Jul; 9(7):977-982. PubMed ID: 28294577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled salbutamol and doping control: effects of dose on urine concentrations.
    Sporer BC; Sheel AW; Taunton J; Rupert JL; McKenzie DC
    Clin J Sport Med; 2008 May; 18(3):282-5. PubMed ID: 18469572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
    Striegel H; Rössner D; Simon P; Niess AM
    Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary and blood concentrations of beta2-agonists in trained subjects: comparison between routes of use.
    Pichon A; Venisse N; Krupka E; Pérault-Pochat MC; Denjean A
    Int J Sports Med; 2006 Mar; 27(3):187-92. PubMed ID: 16541373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta2-Agonist Doping Control and Optical Isomer Challenges.
    Jacobson GA; Fawcett JP
    Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening procedure for beta-adrenergic drugs in sports drug testing by immunological methods.
    Ventura R; González G; Smeyers MT; de la Torre R; Segura J
    J Anal Toxicol; 1998; 22(2):127-34. PubMed ID: 9547409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of inhaled salbutamol in equine urine by ELISA and GC/MS2.
    Eenoo PV; Delbeke FT
    Biomed Chromatogr; 2002 Dec; 16(8):513-6. PubMed ID: 12474214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of salbutamol and detection of other beta-agonists in human postmortem whole blood and urine by GC-MS-SIM.
    Black SB; Hansson RC
    J Anal Toxicol; 1999; 23(2):113-8. PubMed ID: 10192415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance-enhancing substances: what athletes are using.
    Krcik JA
    Cleve Clin J Med; 2001 Apr; 68(4):283, 288-9, 295-7 passim. PubMed ID: 11326808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of β-agonists by HPLC/ESI-MS(n) in horse doping control.
    Garcia P; Paris AC; Gil J; Popot MA; Bonnaire Y
    Biomed Chromatogr; 2011 Jan; 25(1-2):147-54. PubMed ID: 21204111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residue screening for the beta-agonists clenbuterol, salbutamol and cimaterol in urine using enzyme immunoassay and high-performance liquid chromatography.
    Meyer HH; Rinke L; Dürsch I
    J Chromatogr; 1991 Apr; 564(2):551-6. PubMed ID: 1678746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Futility of current urine salbutamol doping control.
    Heuberger JAAC; van Dijkman SC; Cohen AF
    Br J Clin Pharmacol; 2018 Aug; 84(8):1830-1838. PubMed ID: 29722428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of salbutamol enantiomers in human urine by reversed-phase high performance liquid chromatography after derivatization with 2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl isothiocyanate.
    Kim KH; Kim TK
    Arch Pharm Res; 1998 Apr; 21(2):217-22. PubMed ID: 9875434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of salbutamol enantiomers in human plasma and urine by chiral high-performance liquid chromatography.
    Boulton DW; Fawcett JP
    J Chromatogr B Biomed Appl; 1995 Oct; 672(1):103-9. PubMed ID: 8590921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The asthmatic athlete: inhaled Beta-2 agonists, sport performance, and doping.
    McKenzie DC; Fitch KD
    Clin J Sport Med; 2011 Jan; 21(1):46-50. PubMed ID: 21200170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.